Blockchain Registration Transaction Record

New Brain Institute Introduces SPRAVATO™ Ketamine Therapy for Treatment-Resistant Depression

New Brain Institute introduces SPRAVATO™, an FDA-approved ketamine therapy for treatment-resistant depression in adults. This novel approach to treating depression offers hope to patients who have not found relief with traditional antidepressants.

The introduction of SPRAVATO™ by New Brain Institute is significant as it provides a novel approach to treating depression for patients who have not found relief with traditional antidepressants. This therapy offers hope and a potential game-changer in mental health care, with minimal side effects and extensive monitoring by healthcare professionals to ensure patient safety and well-being.